Recommended
July 10, 2025
VSY Biotechnology Enters the Japanese Market!
Sinusoidal Trifocal Technology® developed by VSY Biotechnology has been officially approved in Japan.
Breaking News
Precautionary Recall Announced for Specific Batch of Zaditen Eye Drops in the UK
Jul 09, 2025
A class 2 medicines recall has been issued in the United Kingdom for Zaditen 0.25 mg/ml eye drops solution after Laboratoires Théa notified the MHRA of a manufacturing event that may elevate the risk of microbial contamination.
ViGeneron Rebrands as VeonGen, Earns FDA RPDD for Gene Therapy
Jun 16, 2025
VeonGen Therapeutics has officially announced its rebranding from ViGeneron, marking a strategic transformation into a clinical-stage genetic medicine company dedicated to developing innovative gene therapies for diseases with high unmet medical needs.
FDA Approves Amneal’s Prednisolone Acetate Ophthalmic Suspension for Steroid-Responsive Ocular Inflammation
Jun 13, 2025
Amneal Pharmaceuticals has announced that the U.S. Food and Drug Administration (FDA) has approved its prednisolone acetate ophthalmic suspension, 1%, a sterile topical anti-inflammatory agent intended for steroid-responsive ocular inflammation.
.jpg)
Industry News
Nicox Partners with Kowa for U.S. and Global Commercialization of NCX 470
Jul 18, 2025
Nicox S.A. has entered into a significant licensing agreement with Kowa Company, Ltd., granting Kowa the exclusive rights to develop and commercialize NCX 470 in the United States and all other unlicensed territories worldwide.
FDA Accepts Aldeyra’s Resubmitted NDA for Reproxalap in Dry Eye Disease
Jul 18, 2025
The U.S. Food and Drug Administration (FDA) has accepted for review Aldeyra Therapeutics’ resubmitted New Drug Application (NDA) for reproxalap, an investigational therapy intended to treat the signs and symptoms of dry eye disease (DED).
Harrow Secures Exclusive U.S. Rights to Samsung Bioepis’ Ophthalmology Biosimilars Portfolio
Jul 18, 2025
Harrow has announced a definitive commercialization agreement with Samsung Bioepis, granting Harrow the exclusive U.S. commercial rights to Samsung Bioepis’ ophthalmology biosimilars portfolio.
Ophthalmic Research News
Cancer Drug PRL3-zumab Shows Promise as Novel Treatment for Blinding Eye Diseases
Jul 17, 2025
Researchers in Singapore have uncovered a promising new therapeutic use for PRL3-zumab, an experimental cancer drug originally developed at the ASTAR Institute of Molecular and Cell Biology (ASTAR IMCB).
Relative Peripheral Refraction Found to Predict Myopia Progression in Children
Jul 04, 2025
New research published online in the American Journal of Ophthalmology has shown that vertical and horizontal relative peripheral refraction (RPR) are associated with faster axial length progression and an increased risk of developing myopia in children.
Study Reveals Key Role of ADAM10 in Retinal Disease Development
Jul 02, 2025
New research highlights ADAM10’s role in abnormal retinal blood vessel growth, suggesting novel targets beyond anti-VEGF for diseases like diabetic retinopathy and AMD.
Ophthalmic Blog
AI in Ophthalmology: Top Artificial Intelligence Tools Transforming Eye Health
Mar 07, 2025
The AI in ophthalmology sector is evolving rapidly, introducing Artificial Intelligence tools in ophthalmology that enhance diagnostic accuracy, efficiency, and accessibility.
2024 Recap: Top 8 Groundbreaking Innovations in Eye Disease Therapies and Technologies
Dec 23, 2024
The year 2024 has been a remarkable period for advancements in ophthalmology, with groundbreaking innovations reshaping the landscape of eye disease treatment and diagnosis.
2024 Recap: Top 8 FDA Approvals in Ophthalmology
Dec 16, 2024
The year 2024 has been a pivotal one for ophthalmology, with several novel FDA approvals introducing innovative treatments and technologies to the field
Ophthalmology Breaking News Subscribe